Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20469627 | 0.92 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13055402 | 0.90 | CYP17A1 (0.59) | SMN1; SMN2L3MBTL1NAMPTCYP17A1PSMB8 | |
| SCHEMBL19853212 | 0.89 | NAMPT (0.54) | SMN1; SMN2MEN1KMT2AL3MBTL1NAMPT | |
| SCHEMBL28298376 | 0.87 | NAMPT (0.52) | SMN1; SMN2L3MBTL1NAMPTCYP17A1PDK1 | |
| SCHEMBL907174 | 0.87 | NR1H4 (0.56) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20657635 | 0.87 | NAMPT (0.44) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1138925 | 0.86 | EPHX2 (0.59) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL20657636 | 0.85 | UQCRB (0.63) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL23619661 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL20865536 | 0.85 | CYP17A1 (0.68) | SMN1; SMN2HTTKIF11L3MBTL1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2023-05-16 | — | — | US | disclosed |
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-23 | — | — | US | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | SMN1; SMN2 1162/4885MEN1 3426/4885KMT2A 997/4885 |
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | ABCG2, ABCC1, GLS | SMN1; SMN2 1963/4885MEN1 3031/4885KMT2A 1004/4885 |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | SMN1; SMN2 2020/4885MEN1 454/4885KMT2A 437/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | SMN1; SMN2 3026/4885MEN1 1241/4885KMT2A 1463/4885 |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ESRRG, NR5A2, RXFP4 | SMN1; SMN2 3263/4885MEN1 1585/4885KMT2A 3695/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | SMN1; SMN2 4833/4885MEN1 1085/4885KMT2A 1782/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | SMN1; SMN2 3927/4885MEN1 4301/4885KMT2A 2424/4885 |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | NOTCH1, CHUK, CBFB | SMN1; SMN2 4745/4885MEN1 2299/4885KMT2A 956/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | SMN1; SMN2 1830/4885MEN1 2968/4885KMT2A 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.